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Abstract
AIM: The aim of our study was to determine the effect of adjunctive use of dexmedetomidine and metoral with 
thiopental on hemodynamic status, agitation, patient satisfaction, and duration of seizure in patients with mood 
disorders in electroconvulsive therapy (ECT). 
METHODS: This study is a randomized, double-blind, clinical trial. Sixty patients (18–60 years) according to DSM5 
criteria had mood disorder and were candidates for ECT. Patients were randomly divided into two groups of 30 
each. One group received 5.0 μg/kg dexmedetomidine 10 min before induction of thiopental, and the other group 
received 5.2 mg intravenous metoprolol immediately before ECT. Patients’ satisfaction, duration of seizure, and 
arterial oxygen saturation were evaluated. 
RESULTS: The mean age of both groups was approximately 37 years with the majority of men. No significant 
difference was found between the two groups in terms of age and sex, blood pressure (BP), heart rate (HR), duration 
of seizure, and arterial oxygen saturation before ECT. The mean BP and HR in the recovery were lower in the 
dexmedetomidine group than in the metoral group. Arterial oxygen saturation percentage was not significantly 
different between the two groups. The recovery time in the dexmedetomidine group was longer than the metoral 
group (p = 0.001). Post-ECT satisfaction was found to be higher in the dexmedetomidine group than in the metoral 
group and the mean agitation score was found to be higher in the metoral group. 
CONCLUSION: Both metoral and dexmedetomidine as adjuvants decrease the hyperdynamic responses of patients 
after ECT, whereas the effect of dexmedetomidine is more than metoral; on the other hand, neither dexmedetomidine 
nor metoral has any negative effect on seizure duration, but dexmedetomidine significantly prolonged recovery time 
as compared to metoral. 
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Introduction
Mood disorders, sometimes called affective 
disorders, consist of major depressive disorder (MDD), 
bipolar disorder, and other mood disorders. Patients with 
major depressive episodes are often referred to as MDD 
or unipolar. Patients with manic episode or both manic 
and hypomanic episodes are considered as bipolar 
disorder. A complete diagnostic evaluation must first be 
performed to treat patients with mood disorders and then 
a treatment plan can be implemented [1]. At present, 
existing treatments place particular emphasis on drug 
therapy combined with psychotherapy; however, the 
use of electroconvulsive therapy (ECT) may be the best 
and fastest approach in treatment-resistant depression, 
psychotic patients, those with suicidal thoughts, and 
pregnant mothers with severe depression or mania [2].
ECT is one of the most effective treatments for 
many diseases [3], which has been found to be a safe and 
effective choice for the treatment of mood disorders [4].
ECT causes seizures by electrical impulses 
of varying frequencies through electrodes placed on 
the scalp [5]. ECT has little risk and is one of the safe 
methods used for treatment under general anesthesia. 
The estimated risk of serious complications is about 
1/1000, which is similar to general anesthesia for 
small medical procedures. One of the complications of 
electric shock is sudden parasympathetic release at the 
moment of electric shock, which anticholinergic drugs 
are often used to reduce this complication before an 
electric shock. Immediately after the parasympathetic 
release, the sympathetic system activates, increasing 
the patient’s heart rate (HR) and blood pressure (BP), 
and even causes cardiac arrhythmias, such as fluttering 
sensation (palpitations) and atrial fibrillation [3]. 
Although ECT is a very safe treatment and has no 
absolute contraindication, both the physician and the 
patient must be aware of a number of side effects, 
such as cognitive impairment, which is rapidly resolved 
in most cases. Rarely, it causes seizures, short-term 
complications such as headaches, muscle aches, 
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nausea, vomiting, and fatigue [6]. Different drugs are 
applied to induce anesthesia in patients. The effect 
of anesthetic drugs during treatment with ECT is 
important in several respects including possible effects 
on patients’ mental status, effects on seizure duration, 
as well as different effects of anesthetic drugs on 
maintaining cardiovascular stability in patients. In other 
words, a drug is more favorable for inducing anesthesia 
to produce longer seizures and at the same time a more 
stable cardiovascular condition. Various drugs are 
currently used for this purpose, including metoprolol, 
methohexital, propofol, and dexmedetomidine [7].
Dexmedetomidine is a selective α2 agonist 
that predominantly affects the locus ceruleus [8]. 
Dexmedetomidine attenuates central nervous system 
stimulation by reducing the release of presynaptic 
norepinephrine, causing sedative, more broadly, 
analgesic, anxiolytic, and sympatholytic effects without 
effect on the respiratory system.
The hypodynamic responses to ECT 
are associated with an acute increase in plasma 
epinephrine and norepinephrine concentrations [9]. 
The most common side effects of dexmedetomidine 
are due to its mechanism of action, including 
hypotension and bradycardia. Metoprolol (selective 
β1 blocker) is a common drug for reducing cardiac 
output, HR, and BP and its peak is 15–20 min after 
intravenous injection [10]. Therefore, both metoprolol 
and dexmedetomidine can be effective in controlling 
the hemodynamic symptoms of ECT [11]. To date, no 
comparable studies have compared dexmedetomidine 
and metoral in combination with anesthetics for 
ECT. Therefore, we decided to compare the effect of 
adding dexmedetomidine and metoral to thiopental on 
hemodynamic status, agitation, patient satisfaction, 
and duration of seizure in patients with mood disorders 
who were candidates for ECT.
Methods
This study is a double-blind randomized clinical 
trial which was performed on 18–60 years old patients 
with mood disorder referred to Amir Kabir Hospital in 
Arak, Iran. ECT candidates were randomly divided into 
two groups of dexmedetomidine and metoral using 
randomized complete block design and data were 
collected through checklist. If they had inclusion criteria, 
they were included in the study.
Inclusion criteria included: (1) All patients with 
mood disorders who are candidates for ECT, (2) having 
a form of informed consent, and (3) average age of 
18–60 years. Exclusion criteria included: (1) All patients 
with cardiopulmonary arrest after induction of anesthesia 
during ECT, (2) all patients who need intubation after 
ECT due to prolonged apnea and respiratory failure, 
and (3) all patients who do not develop seizures during 
the ECT process.
In the present study, informed consent for 
participation in the research was completed for each 
patient. Patients were then placed on an ECT bed in 
a supine position and an intravenous line was inserted 
by a No. 20 Angiocath. Patients were given about 1–3 
ml/kg of fluid before anesthesia as CVE. Necessary 
monitoring was performed for patients including HR, 
RR, arterial blood oxygen saturation, and NIBP.
For the purpose of blindness, the drugs were 
pre-prepared by the anesthesiologist responsible for the 
design and made available to the anesthesiologist resident 
who was unaware of the type of medication. In both drug 
groups (dexmedetomidine and metoral), the syringes were 
the same, the volume of the drug injections reached 10 
cc. In Group A, 0.5 μg/kg intravenous dexmedetomidine 
was injected before anesthesia. For double blinding, the 
drug was reached to 10 ml with normal saline. Then, the 
anesthesia was induced by intravenous injection of 2–3 mg/
kg thiopental and intramuscular injection of succinylcholine 
0.5 mg/kg in both groups. At this stage, 0.5 mg intravenous 
atropine, a short-acting anticholinergic agent to reduce the 
effects of parasympathetic release at the moment of electric 
shock, was injected in both groups. After anesthesia and 
immediately before stimulation with ECT, 2.5 mg of metoral 
was injected for Group B to be at the peak of its effect 
at the time of sympathetic release, which occurs a few 
seconds after the shock, and during sympathetic effects 
of metoral. Ventilation was performed with 100% oxygen 
for all patients. After complete anesthesia, electric shock 
was applied bilaterally with the amount of energy required 
by the psychiatrist. Then, the data obtained from patients 
regarding hemodynamic symptoms, seizure duration, 
recovery time, agitation score, satisfaction, and arterial 
blood oxygen saturation were recorded by the resident in 
a questionnaire. Explanation that the agitation score was 
recorded as objective by the resident in the questionnaires 
after observing the patients. Subjective satisfaction was 
recorded by questioning patients. The questionnaires were 
completed by the psychiatry resident who was unaware of 
the type of medication.
Agitation score
1. Sleepy
2. Awake and peaceful
3. Irritable and noisy
4. Disconsolate noisy
5. Severe blenched or willing to wake up from 
bed or sitting on the bed and shrieking
Satisfaction score
1. Happy and peaceful
2. Without rumble and not bad satisfaction
3. Having no acquiescence or moderate 
satisfaction
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4. Patient unsatisfaction and shows that patient 
does not like any same treatment
Calculation of the sample size
The sample size was 30 people in each group 
according to the following formula and 5 people in each 
group were considered for sample loss during the study.
z1−α2=1.96 z1−β=1.28 
( )α β δ δ
µ µ
− + − +
−
2
2
1 1 2 2
2
1 2
( )2:
( )
z z
n
μ1=33.2  μ2=29.2
δ=4.7     δ=3.9
Data analysis
Data were statistically analyzed using the 
SPSS software version 19. Data were analyzed using 
t-test. ANOVA test, Chi-square, and the results were 
indicated as graphs and tables.
Ethical considerations
A written letter was received from university 
officials to introduce us to the research centers. 
A written letter was obtained from the respected 
authorities of the selected research centers. The 
purpose of the study was described for all research 
units and their written consent was obtained. All 
patients’ information was kept confidential by the 
plan’s administrator. In all stages of research, all 
Helsinki Research Ethics Statements and Research 
Ethics Committees were considered. Ethic code of 
IR.ARAKMU.REC.1397.044 was approved for this 
study. The registration code at the Iran Clinical Trial 
Center for this project is IRCT20141209020258N87.
Results
The addition of dexmedetomidine and metoral 
to thiopental in patients with hemodynamic status and 
duration of seizure was evaluated. According to Table 1, 
the mean age of both groups was approximately 
37 years and the majority were male (70%). There 
was no significant difference between the two groups 
in terms of age, sex, hemodynamic parameters, mean 
arterial BP, HR, and oxygen saturation before ECT.
Table 1: Comparison of age and sex distribution of patients 
with mood disorders
Groups Dexmedetomidine group Metoral group p value
Age 7.2  ±  8.37 1.1  ±  9.36 0.1
Sex (%)
Male 7.70 8.68 0.2
Female 3.29 2.31
Table 2 indicates mean BP, HR, and arterial 
oxygen saturation before shock therapy, and no 
significant differences were found between the two 
groups in mean BP, HR, and arterial oxygen saturation 
before ECT (p = 0.4, p = 0.6).
Comparison of mean BP, HR, and arterial 
oxygen saturation after ECT (recovery) is indicated 
in Table 3, there was a significant difference between 
the two groups in mean recovery of patients’ mean 
BP and HR. The mean BP and HR of patients in the 
dexmedetomidine group were lower than that of 
the metoral group (p = 0.02, p = 0.01). However, no 
significant difference was found in arterial oxygen 
saturation in recovery (p = 0.4).
Table 3: Comparison of mean blood pressure and heart rate 
and arterial oxygen saturation after ETC (recovery)
Group Dexmedetomidine group Metoral group p value
Mean recovery arterial blood 
pressure
1.4  ±  9.80 9.4  ±  6.86 0.02
Mean recovery heart rate 2.3  ±  3.80 3.6  ±  2.88 0.01
Mean arterial oxygen saturation 
recovery
1.5  ±  2.94 6.5  ±  1.92 0.4
ECT: Electroconvulsive therapy.
According to Table 4 and Figure 1, no significant 
difference was found between the two groups in terms 
of seizure duration (p = 0.08). However, there was a 
significant difference between the two groups in terms 
of recovery time (in min). Significantly, the recovery 
time was significantly longer in the dexmedetomidine 
group as compared to metoral group (p = 0.03).
Table 4: Comparison of duration of seizure and average 
duration of recovery in patients with mood disorders
Group Dexmedetomidine group Metoral group p value
Duration of seizures (in s) 1.2  ±  4.27 3.4  ±  1.30 0.08
Duration of recovery (in min) 3.1  ±  8.15 2.3  ±  7.11 0.03
According to Table 5, a significant difference 
was found in satisfaction score between the two 
groups so that the level of satisfaction was found to 
be higher in the dexmedetomidine group than in the
Figure 1: Comparison of duration of seizure and mean recovery time 
in patients with mood disorders
metoral group. In terms of post-ECT agitation score, 
the score of agitation was significantly higher in the 
Table 2: Comparison of mean blood pressure, heart rate, and 
arterial oxygen saturation before ECT
Group Dexmedetomidine group Metoral group p value
Mean arterial blood pressure before 
shock
9.2  ±  8.90 4.6  ±  3.92 0.4
Heart rate before shock 7.3  ±  8.100 2.5  ±  7.95 0.6
Arterial oxygen saturation before 
shock
6.4  ±  2.95 2.4  ±  1.94 0.4
ECT: Electroconvulsive therapy.
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metoral group and agitation rate was higher in this 
group. (Score agitation in dexmedetomidine group was 
approximately 2), (p = 0.3).
Table 5: Comparison of satisfaction score and agitation score 
in patients with mood disorders
Group Dexmedetomidine group Metoral group p value
Satisfaction score 98.0 ± 38.1 1.1 ± 67.2 0.3
Agitation score 85.0 ± 87.1 98.0 ± 41.3 0.3
Discussion
A complete diagnostic evaluation must first be 
performed to treat patients with mood disorders and then a 
treatment plan is implemented [12]. The current therapies 
focus on drug therapy with psychotherapy, however, in 
depressed patients, ECT may be the best and fastest 
treatment [13]. The impact of ECT has been indicated by 
various sources. Since the 1950s, there has also been a 
tendency to concurrent use of ECT and antidepressants 
to increase treatment success, it has been reported 
that ECT is 20–40% more effective than drug therapy 
[14]. The aim of this study was to compare the effects 
of the combination of dexmedetomidine and metoprolol 
with thiopental on hemodynamic status, agitation, and 
satisfaction after ECT in patients with mood disorder. The 
results of this study indicated that there was no significant 
difference in the duration of seizure between the two 
groups. Neither of the two adjuvants had a negative 
effect on the duration of seizures. The results of this 
study demonstrated that the hemodynamic parameters 
were more stable in the dexmedetomidine group than 
in the metoral group. Tachycardia and ECT-induced 
hypertension were inhibited in the dexmedetomidine 
group compared to the remifentanil group. There was a 
significant difference between the two groups in terms of 
satisfaction and agitation score; therefore, satisfaction 
was higher in the dexmedetomidine group than in the 
metoral group (score: 1). Agitation was higher in the 
metoral group and agitation score was higher in this group 
(agitation score in the dexmedetomidine group = 2).
Mason et al. (2013) compared the effect of 
dexmedetomidine and ketamine-propofol anesthesia 
combination before ECT with non-dexmedetomidine 
group. This study was performed on 40 patients 
who received ECT and it was found that adding 
dexmedetomidine was associated with increased 
seizure duration, decreased restlessness, increased 
satisfaction, and a decrease in BP and PR of the patients. 
In our study, dexmedetomidine also led to a significant 
decrease in BP and HR after ECT, and patients’ agitation 
scores decreased in the dexmedetomidine group [15].
In the 2016 study by Aparna et al., 60 patients 
aged 18–60 years scheduled for ECT were evaluated.
The recipient group received dexmedetomidine 
(0.5 μg/kg) diluted to 10 ml with 0.9% saline or 10 ml 
0.9% saline (control) 10 min before induction of 
anesthesia with thiopentone. The increase in MAP 
and HR was lower in the dexmedetomidine group 
compared to the placebo group. Mean agitation score 
was less in dexmedetomidine group and duration 
of convulsion was not different in both groups. In our 
study, dexmedetomidine also reduced BP, HR, and 
decreased post-ECT agitation [16]. In 2016, Aksay et al. 
retrospectively analyzed 7 patients who received 178 
ECT sessions between 2011 and 2015. Their analysis 
revealed that the prevalence of post-ictal agitation was 
lower in dexmedetomidine recipients and it was suggested 
that adjunctive use of dexmedetomidine to S-ketamine 
in ECT may be promising for reducing agitation [1]. 
The results of our study were similar in relation to the 
reduction of agitation in the dexmedetomidine group.
In another study by Moshiri et al., in Iran in 
2016, the effect of dexmedetomidine, alfentanil, and 
placebo on ECT candidate patients was evaluated 
that there was no significant difference between the 
three groups in terms of seizure duration, agitation 
score, and hemodynamic parameters. The recovery 
time was shorter in the control group compared to 
dexmedetomidine and alfentanil. The results of the 
mentioned study have shown that the use of both alfentanil 
and dexmedetomidine as adjuvants did not cause 
significant changes in the hemodynamic parameters 
and duration of ECT-induced seizures [4]. The results 
of this study were inconsistent with our findings, since 
in our study, both adjuvant drugs resulted in a decrease 
in BP and HR after ECT, whereas the decrease was 
higher in the dexmedetomidine group. In other words, 
the ECT-induced hyperdynamic changes were less in 
the dexmedetomidine group. The results of several 
studies indicate that dexmedetomidine completely 
reduces the ECT-induced hyperdynamic responses in 
recovery. While it has no specific effect on the duration 
of seizures or recovery. The results of our study also 
confirm precisely this and indicate that hemodynamic 
stability during recovery and reduction of ECT-induced 
hypodynamic responses to dexmedetomidine. In our 
study, the effect of dexmedetomidine in controlling 
patients’ hyperdynamic responses was higher than 
that of metoral. Both drugs had no adverse effect on 
the duration of seizures. However, the recovery time 
was significantly increased in the dexmedetomidine 
group. It is important to note that agitation score was 
higher in the dexmedetomidine group than in the 
dexmedetomidine group, and patients’ satisfaction with 
recovery was higher in the dexmedetomidine group.
Conclusion
Both dexmedetomidine and metoral as 
adjuvants lead to a decrease in the post-ECT 
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hyperdynamic response of patients. Whereas the effect 
of dexmedetomidine is greater than metoral, on the 
other hand, none of the dexmedetomidine and metoral 
drugs had a negative effect on the duration of seizure. 
Dexmedetomidine significantly prolongs recovery time 
compared to metoral and agitation was also enhanced 
by the use of metoral.
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